Obesity Clinical Trial
— MINDGUTOfficial title:
Exploring the Interplay Between Diet, Obesity, Mental Health, and the Gut Microbiome. The MIND-GUT Digital Pilot Intervention Study.
NCT number | NCT06374407 |
Other study ID # | GT-001 |
Secondary ID | |
Status | Not yet recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | June 2024 |
Est. completion date | December 2026 |
Verified date | April 2024 |
Source | University of Skövde |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This 12-week pilot study aims to evaluate the feasibility and effectiveness of a dietary intervention targeting diet, obesity, mental health, and the gut microbiome in promoting weight loss and enhancing mental health among obese men and women aged 30-50. Participants, excluding those with specific medical conditions, will be randomly assigned to either an intervention or control group using a meal planning smartphone app. Clinical assessments will include anthropometry, mental health questionnaires, dietary recalls, and stool sample collections. The study's endpoints include program retention, adherence, changes in body weight, mental health, and gut microbiome diversity. Statistical analyses will evaluate intervention effects and the potential mediating roles of the gut microbiome. This pilot study has implications for health policies, public healthcare, digital health companies, and the biotech and pharmacology industries. Future plans involve a large-scale intervention study in multiple countries with ongoing collaborations.
Status | Not yet recruiting |
Enrollment | 126 |
Est. completion date | December 2026 |
Est. primary completion date | May 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 30 Years to 50 Years |
Eligibility | Inclusion Criteria: - age 30- 50; - BMI = 30 kg/m2; - stable physical activity; - one person per household; - commitment to full protocol. Exclusion Criteria: - use of psychiatric medications (e.g., serotonin reuptake inhibitors); - use of weight loss medications (GLP-1 receptor agonists); - food allergies affecting adherence to the MIND diet; - diagnosis of eating disorders; - diagnosis of diabetes; - diagnosis of polycystic ovary syndrome; - sensory deficits (e.g., COVID-19-induced loss of taste/smell); - antibiotic use during the latest 3 months; - participation in another study; - language understanding limitations (i.e., not able to understand either Swedish or English); - coeliac/inflammatory bowel disease; - planned weight management program within three months; - pregnancy; - lactation; - menopause. |
Country | Name | City | State |
---|---|---|---|
Sweden | University of Skövde | Skövde |
Lead Sponsor | Collaborator |
---|---|
University of Skövde | Albert Einstein College of Medicine, Göteborg University, Kristianstad University, State University of New York - Downstate Medical Center, The Food Scientist AB (Sweden), University of Pavia, Uppsala University |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Program retention | Evaluation of participants' continued engagement in the program over time i.e., % of individuals completing the second and third 24h diet recall and % of participants returning to the second visit at the end of the intervention. | 12 weeks | |
Primary | Adherence | Measurement of participants' compliance with the assigned diet and program through 24h recall interviews, assessed comparing reported intake frequencies of each food group with the recommended intake frequencies according to the principles of the MIND diet. | 12 weeks | |
Primary | Acceptability | Assessment of participants' experience of the program through qualitative interviews, focusing in particular on: Perception of and experience with the intervention, intervention components (dietary plans, use of the app, etc.), factors influencing participants' engagement, perceived impact on behavior and well-being, interaction with the staff, suggestions for improvement. | 12 weeks | |
Primary | Study effectiveness: change in eating attitudes at follow-up | Comparison of a score calculated after administration of the EAT-26 questionnaire at baseline vs. follow-up. The EAT-26 comprises three subscales, namely, Dieting, Bulimia and Food Preoccupation, and Oral Control. Higher scores correspond to a worse outcome. | 12 weeks | |
Primary | Study effectiveness: change in stress levels at follow-up | Comparison of PSS-4 questionnaire at baseline vs. follow-up. The PSS total score is calculated by reverse-coding the positive items and summing the scores for all items. The total scores range from 0 to 56, from 0 to 40, and from 0 to 16 for the PSS-14, PSS-10, and PSS-4, respectively. A higher score indicates more perceived stress. | 12 weeks | |
Primary | Study effectiveness: change in depression symptoms at follow-up | Comparison of PHQ-9 questionnaire at baseline vs. follow-up. The PHQ-9 is a tool to assist clinicians in identifying and diagnosing major depression. It has a maximum score of 27. Higher scores correspond to worst outcomes in terms of depression symtoms. | 12 weeks | |
Primary | Study effectiveness: change in anxiety symtoms at follow-up | Comparison of GAD-7 questionnaire at baseline vs. follow-up. Each item is scored on a four-point Likert scale (0-3) with total scores ranging from 0 to 21 with higher scores reflecting worst outcomes in terms of anxiety severity. | 12 weeks | |
Primary | Study effectiveness: change in body weight at follow-up | Comparison of body weight at baseline vs. follow-up | 12 weeks | |
Primary | Study effectiveness: change in % total fat mass at follow-up | Comparison of body % total fat mass at baseline vs. follow-up | 12 weeks | |
Primary | Study effectiveness: change in % visceral fat mass at follow-up | Comparison of body % visceral fat at baseline vs. follow-up | 12 weeks | |
Primary | Study effectiveness: change in waist circumference at follow-up | Comparison of waist circumference at baseline vs. follow-up | 12 weeks | |
Primary | Study effectiveness: change in hip circumference at follow-up | Comparison of hip circumference at baseline vs. follow-up | 12 weeks | |
Primary | Study effectiveness: change in microbiome variety at follow-up | Comparison of number and types of species at baseline vs. follow-up. | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |